BCMA-targeting bispecific antibodies treat multiple myeloma by binding to BCMA on malignant plasma cells and directing T-cells to initiate targeted cell killing. This podcast provides updates on the use of BCMA-targeting bispecific antibodies in relapsed/refractory (R/R) multiple myeloma from the 2024 American Society of Clinical Oncology (ASCO) Meeting and the 29th Congress of the European Hematology Association (EHA).

You will hear from Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, who discusses updated data from the MagnetisMM-3 trial (NCT04649359) of elranatamab and real-world findings from a French compassionate use program using this agent. Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, provides insights into the real-world step-up dosing of teclistamab to mitigate toxicities. Finally, Sundar Jagannath, MD, Tisch Cancer Institute at Mount Sinai, New York, NY, discusses a matched adjusted indirect comparison (MAIC) of the novel bispecific linvoseltamab with teclistamab, and the sequencing of bispecific antibodies with CAR T-cells.

The post Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024 appeared first on VJHemOnc.